MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN
DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--04.12.2017--
Biogen (NASDAQ: BIIB) announced today the appointment of Mark Hernon as Senior
Vice President, Chief Information Officer, effective December 4.
In his new role, Mr. Hernon will lead the global information technology (IT)
organization and be responsible for accelerating and supporting Biogen's
operations through delivery of innovative technology capabilities, systems, and
tools that align with Biogen's corporate strategy. Mr. Hernon joins Biogen with
more than 30 years of experience in IT and strategic leadership. In recent
years with Takeda Pharmaceuticals, he was the Regional CIO for the Americas and
Global Head of R&D, QA and HR Systems, as well as VP of Operations for the
Cambridge, MA site. He was most recently the Global Head of R&D Site Strategy
and Operations, where he led the global transformation of Takeda's R&D
'With Mark's years in industry successfully leading global IT and operations
functions, we are extremely pleased to have him join us at Biogen,' said Ms.
Alexander. 'His experience and leadership together with our existing excellent
Biogen IT organization will allow Biogen to continue creating and harnessing
data and information to pioneer new developments in neuroscience.'
Prior to his role with Takeda, Mr. Hernon spent 12 years with Millennial
Pharmaceuticals as CIO and VP Operations, leading strategic initiatives to
streamline the organization, aligning with the business, and managing the
group's transition through the acquisition by Takeda.
'I am excited at the prospect of leading a team of talented and dedicated
individuals focused on enabling Biogen's strategy through the smart application
of technology,' said Mr. Hernon.
Mr. Hernon holds a BS and MS in Industrial and Management Engineering from
Rensselaer Polytechnic Institute, and an MBA from the Lally School of
Management at Rensselaer Polytechnic Institute.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen
discovers, develops and delivers worldwide innovative therapies for people
living with serious neurological and neurodegenerative diseases. Founded in
1978 as one of the world's first global biotechnology companies by Charles
Weissman and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen
has the leading portfolio of medicines to treat multiple sclerosis; has
introduced the first and only approved treatment for spinal muscular atrophy;
and is focused on advancing neuroscience research programs in Alzheimer's
disease and dementia, neuroimmunology, movement disorders, neuromuscular
disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen
also manufactures and commercializes biosimilars of advanced biologics. We
routinely post information that may be important to investors on our website
at www.biogen.com. To learn more, please visit www.biogen.com and follow us on
social media - Twitter, LinkedIn, Facebook, YouTube.
Biogen Safe Harbor
This press release contains forward-looking statements, made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform Act of 1995,
including statements relating to Biogen's business activities, our worldwide
medical function and strategy, and the expected benefits from Dr. Jariwala's
appointment as our Senior Vice President, Worldwide. These forward-looking
statements may be accompanied by words such as 'aim,' 'anticipate,' 'believe,'
'could,' 'estimate,' 'except,' 'forecast,' 'intend,' 'may,' 'plan,'
'potential,' 'possible,' 'will' and other words and terms of similar meaning.
You should not place undue reliance on these statements.
These statements involve risks and uncertainties that could cause actual
results to differ materially from those reflected in such statements,
including, without limitation: risks relating to management and key personnel
changes; failure to compete effectively; difficulties in obtaining and
maintaining adequate coverage, pricing and reimbursement for our products;
potential future healthcare reforms; the occurrence of adverse safety events;
failure to protect and enforce our data, intellectual property and other
proprietary rights and uncertainties relating to intellectual property claims
and challenges; uncertainty of success in developing, licensing or acquiring
other product candidates or additional indications for existing products; delay
in approval of our drug candidates; product liability claims; and third party
collaboration risks. The foregoing sets forth many, but not all, of the factors
that could cause actual results to differ from our expectations in any
forward-looking statement. Investors should consider this cautionary statement,
as well as the risk factors identified in Biogen's most recent annual or
quarterly report and in other reports Biogen has filed with the U.S. Securities
and Exchange Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this press release. We do not
undertake any obligation to publicly update any forward-looking statements,
whether as a result of new information, future developments or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/
Matt Fearer, +1 781-464-3260
Mike Henke, +1 781-464-2442
04.12.2017 Veröffentlichung einer Pressemitteilung, übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de